Leech AA - Search Results

1

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.

Nguyen JT, Cole AL, Leech AA, Wood WA, Dusetzina SB. Nguyen JT, et al. Among authors: leech aa. Value Health. 2020 Oct;23(10):1292-1299. doi: 10.1016/j.jval.2020.05.019. Epub 2020 Aug 7. Value Health. 2020. PMID: 33032772 Free article.

2

Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Thokala P, Ochalek J, Leech AA, Tong T. Thokala P, et al. Among authors: leech aa. Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1. Pharmacoeconomics. 2018. PMID: 29427072 Free article. Review.

3

Use and Misuse of Cost-Effectiveness Analysis Thresholds in Low- and Middle-Income Countries: Trends in Cost-per-DALY Studies.

Leech AA, Kim DD, Cohen JT, Neumann PJ. Leech AA, et al. Value Health. 2018 Jul;21(7):759-761. doi: 10.1016/j.jval.2017.12.016. Epub 2018 Feb 21. Value Health. 2018. PMID: 30005746 Free PMC article.

4

Cost-Effective But Unaffordable: The CAR-T Conundrum.

Leech AA, Dusetzina SB. Leech AA, et al. J Natl Cancer Inst. 2019 Jul 1;111(7):644-645. doi: 10.1093/jnci/djy195. J Natl Cancer Inst. 2019. PMID: 30561705 No abstract available.

5

Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.

Lin PJ, D'Cruz B, Leech AA, Neumann PJ, Sanon Aigbogun M, Oberdhan D, Lavelle TA. Lin PJ, et al. Among authors: leech aa. Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3. Pharmacoeconomics. 2019. PMID: 30903567

6

Balancing Value with Affordability: Cell Immunotherapy for Cancer Treatment in the U.S.

Leech AA, Neumann PJ, Cohen JT, Jagasia M, Dusetzina SB. Leech AA, et al. Oncologist. 2020 Jul;25(7):e1117-e1119. doi: 10.1634/theoncologist.2020-0025. Epub 2020 May 11. Oncologist. 2020. PMID: 32386072 Free PMC article.

7

Author's Reply.

Nguyen JT, Cole AL, Leech AA, Wood WA, Dusetzina SB. Nguyen JT, et al. Among authors: leech aa. Value Health. 2021 Jul;24(7):1086-1087. doi: 10.1016/j.jval.2020.12.025. Epub 2021 Apr 20. Value Health. 2021. PMID: 34243833 Free article. No abstract available.

8

Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy.

Sampson C, Zamora B, Watson S, Cairns J, Chalkidou K, Cubi-Molla P, Devlin N, García-Lorenzo B, Hughes DA, Leech AA, Towse A. Sampson C, et al. Among authors: leech aa. Appl Health Econ Health Policy. 2022 Sep;20(5):651-667. doi: 10.1007/s40258-022-00730-3. Epub 2022 Jun 7. Appl Health Econ Health Policy. 2022. PMID: 35668345 Free PMC article. Review.

9

Cost-effectiveness of preexposure prophylaxis for HIV prevention for conception in the United States.

Leech AA, Burgess JF, Sullivan M, Kuohung W, Horný M, Drainoni ML, Christiansen CL, Linas BP. Leech AA, et al. AIDS. 2018 Nov 28;32(18):2787-2798. doi: 10.1097/QAD.0000000000002014. AIDS. 2018. PMID: 30234602 Free PMC article.

10

Modelling the potential cost-effectiveness of food-based programs to reduce malnutrition.

Webb P, Danaei G, Masters WA, Rosettie KL, Leech AA, Cohen J, Blakstad M, Kranz S, Mozaffarian D; Global Nutrition and Policy Consortium. Webb P, et al. Among authors: leech aa. Glob Food Sec. 2021 Jun;29:100550. doi: 10.1016/j.gfs.2021.100550. Glob Food Sec. 2021. PMID: 34164258 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

35 results

Search Page